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Evaluable Patients (N¼30)
Age at enrollment (years)
Mean(SD) 7.7 (4.7)
Median (range) 6.9 (2.2-17.3)
Age at enrollment (years)
2-3.99 10 (33%)
4 or older 20 (67%)
Stem Cell Source
Cord blood 5 (16%)
Marrow 21 (70%)
Marrow and cord blood 1 (3%)
PBSC 3 (10%)
Stage of Acute GI GVHD for
patients alive through Day 100
0 21 (78%)
1 2 (7%)
2 1 (4%)
3 3 (11%)
Overall Grade of Acute GVHD for
patients alive through Day 100
0 20 (74%)
2 4 (15%)
3 3 (11%)
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medulloblastoma. Norovirus was detected by RNA RT-PCR
test of stool performed by Focus Diagnostics, Cypress, Ca. The
dose of Nitazoxanide was 100mg po BID for ages 1 to 4 years,
200 mg po BID for age 4 to 11 years, and 500 mg po BID for
greater than 11 years.
1 pt, 33 months post allo HSCT with normal immune
studies was not treated as symptoms resolved prior to test
result. All other pts clinically responded with improvements
in diarrhea, nausea, and abdominal pain in 2-4 days (median
2 days). 3 pts were pre-HSCT on chemo/immunotherapy and
11 were 17 days to 34 months after HSCT. All the treated pts
were on immune suppression or chemotherapy. 9 allo HSCT
pts were on immunosuppression and 5 of these had GVHD at
onset of symptoms. Immune suppression included tacroli-
mus/solumedrol (3), cellcept/solumedrol (2) plus inﬂiximab
(1), tacrolimus (1), cyclosporine (1), tacrolimus/cellcept (1). 3
pts were receiving immunotherapy (1), or chemotherapy for
solid tumors (2) prior to planned HSCT. 1 pt was 10 months
post auto HSCT. Clearance of stool virus was variable. 2/3 pts
treated prior to HSCT became negative on stool study within
5-14 days of treatment (1 unknown duration). Among pts
treated after HSCT 4/9 had persistent viral shedding, 2
received drug until death (1 adenovirus, 1 CHF) both were
treated greater than 2 months, 3 with GVHD still shed virus
after 6 months of treatment, and 4 are off therapy and
remain negative for norovirus RNA. 1 auto HSCT pt stopped
viral shedding 2 months post starting Nitazoxanide. 2 HSCT
pts with clinical resolution but persistent viral shedding
stopped treatment and had clinical symptoms return. These
pts responded to restarting therapy within 2 days but
continue to shed virus. UGI endoscopy/colonoscopy were
performed in 5 pts at the time of infection, all showed
inﬂammation/edema but no GVHD was seen on histology.
Peripheral blood CD4 counts among those with persistent
viral shedding ranged from <50-445/ul and for those that
cleared virus 143-1222/ul.
Nitazoxanide is effective therapy for norovirus gastroen-
teritis in immune compromised patients. Therapy needs to
be continued until stool RNA studies become negative.359
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Myeloablative regimens are associated with prolonged
periods of cachexia/anorexia, nausea/vomiting, mucositis,
and compromised gut integrity (CGI). Studies suggest that
CGI could increase the risk of developing acute Graft versus
Host Disease (aGVHD). Preserving gastrointestinal integritymay decrease the risk of aGVHD which occurs in approxi-
mately 35% of children undergoing allogeneic HCT. Probiotics
(nutritional supplements that contain viablemicroorganisms
and confer a beneﬁt to the host) have emerged as a possible
therapeutic agent in preserving gut integrity. Animal studies
have found that administration of probiotics reduced the
incidence of aGVHD when compared to placebo. Clinical
trials in children with HIV infections and adults receiving
organ transplants have found probiotics to reduce morbidity
andmortality. Prior to our Pilot Trial, probiotics had not been
investigated in the HCT setting. This pilot study evaluated the
safety and feasibility of probiotics administered to children
undergoing allogeneic HCT. Patients received once daily
supplementationwith L.plantarum 299v (1 x107 CFU/kg/day)
beginning on Day e 7 and continued until Day + 14. Thirty-
one patients who were undergoing myeloablative allogeneic
HCT were enrolled. One patient was not evaluated for safety
because only one dose was given and the patient withdrew
from the study. Safety: Of 30 evaluable patients, there were
no cases of Lactobacillus plantarum bacteremia (0% (0/30)
with 95% exact binomial CI (0%, 12%)). Feasibility: Of the 31
eligible patients, only one (#12) received < 50% of the dose.
Therefore, 97% of the eligible patients (30/31), 95% CI (83%-
100%), received at least 50% of the probiotic dose. Clos-
tridium difﬁcile infections were noted in 20% of the patients
by Day + 100. Non-lactobacillus bacteremia was noted in 23%
of evaluable patients. Three patients died before Day + 100,
but no deaths were associated with lactobacillus adminis-
tration. Stage 1-3 acute gastrointestinal aGVHD was noted in
22% of patients who survived to Day + 100. The overall
incidence of Grades II-III GVHD was 26%. No patients had
Grade 4 GVHD. Lactobacillus plantarum can safely and
feasibly be administered to children undergoing myeloa-
blative HCT.360
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